SynthesisClinical drug investigation2009
Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials.
Synthesis in Clinical drug investigation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Efficacy of anti-osteoporosis treatment for men with osteoporosis: a meta-analysis.Journal of bone and mineral metabolism · 2023Pooled it
- Protocol for the models of primary osteoporosis screening in men (MOPS) cluster randomized trial.Contemporary clinical trials · 2022Article
- Comparison of screening strategies for prevalent vertebral fractures in South Korea: vertebral fracture assessment vs. spine radiography.BMC musculoskeletal disorders · 2018Article
- Comparison of fracture risk assessment tools in older men without prior hip or spine fracture: the MrOS study.Archives of osteoporosis · 2017Article
- Time to Osteoporosis and Major Fracture in Older Men: The MrOS Study.American journal of preventive medicine · 2016Article
- Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality.Arthritis research & therapy · 2012Review
- Heterogeneity of biological bone markers in idiopathic male osteoporosis.Rheumatology international · 2012Article
- Therapeutic options for low bone mineral density in HIV-infected subjects.Current HIV/AIDS reports · 2012Article
- Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.Clinical drug investigation · 2012Article
- Osteoporosis in men.Journal of osteoporosis · 2012Article
- Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study.Journal of bone and mineral metabolism · 2011Article
Corrections and comments
- Retraction · 2021-01-28Cites Retracted Work · Concerns/Issues about Data · · Meta-analysis included works by Yoshihiro Sato, which were later retracted; Yoshihiro Sato has an institutional finding of misconduct;
- Retracted
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveMale osteoporosis is an important public health issue and remains undertreated. We performed this meta-analysis to clarify the anti-fracture efficacy of risedronic acid in men.
methodsRandomized controlled trials (RCTs) in men receiving risedronic acid or placebo published between 1980 and September 2008 were searched for in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. Studies with a follow-up of at least 12 months and providing the incidence of fractures were considered for inclusion in the review. Two independent reviewers assessed the methodological quality of the included studies and performed data extraction. Analysis of pooled data was carried out using Revman 4.2 software.
resultsFour RCTs met the inclusion criteria and permitted a pooled estimate of effectiveness. Relative risk with 95% confidence intervals for pooled effect under fixed effects model were: 0.31 (0.16, 0.60) for vertebral fractures and 0.40 (0.23, 0.70) for nonvertebral fractures, suggesting a 69% risk reduction of vertebral fractures and a 60% risk reduction of nonvertebral fracture with risedronic acid treatment in men.
conclusionThe results of this meta-analysis show that risedronic acid treatment is associated with a reduced risk of fractures in men.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.